Literature DB >> 26069487

Radiotherapy and risks of tumor regrowth or inducing second cancer.

Emad Y Moawad1.   

Abstract

Considerable research is aimed at determining the mechanism by which tumor cures, or regrows or second cancer develops, to be predictable and controllable. The wide range of doses, from low to very high, estimated statistically is responsible for such risks. A mathematical model is presented that describes both: the growth due to lower or over irradiated doses or the post therapy relapse of human cancer, and the shrinkage due to either of over irradiated doses, or appropriate irradiated doses. Simulations of the presented model showed that the initial tumor energy, administered dose energy, and their subsequent summation of tumor regrowth energy are always balanced with summation of Whole Body Cell Energy Burden during all treatment phases. Tumor regrows if its energy is higher than that of the dose, or if the increase of dose energy from that of the tumor is less than the one required to complete its shrinkage path. Patient-specific approaches that account for variations in tumor energies should enable more accurate dose estimates and, consequently, better protection against either lower or over irradiation that could lead to tumor regrowth and increase risks of second cancer.

Entities:  

Keywords:  Curing time; Lower irradiated dose treatment; Over irradiated dose treatment; Summation of tumor growth energy; Whole Body Cell Energy Burden

Year:  2011        PMID: 26069487      PMCID: PMC4451625          DOI: 10.1007/s12645-011-0018-4

Source DB:  PubMed          Journal:  Cancer Nanotechnol        ISSN: 1868-6958


  29 in total

1.  Helical tomotherapy radiation leakage and shielding considerations.

Authors:  John Balog; Dan Lucas; Cleber DeSouza; Rick Crilly
Journal:  Med Phys       Date:  2005-03       Impact factor: 4.071

2.  Childhood cancer--treatment at a cost.

Authors:  Elaine Ron
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

3.  Potential doubling time and clinical outcome in head and neck squamous cell carcinoma treated with 70 GY in 7 weeks.

Authors:  J Bourhis; R Dendale; C Hill; J Bosq; F Janot; P Attal; A Fortin; P Marandas; G Schwaab; P Wibault; E P Malaise; S Bobin; B Luboinski; F Eschwege; G Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-06-01       Impact factor: 7.038

Review 4.  Hypoxia and adaptive landscapes in the evolution of carcinogenesis.

Authors:  Robert J Gillies; Robert A Gatenby
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

5.  Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft.

Authors:  E C Barendswaard; J L Humm; J A O'Donoghue; G Sgouros; R D Finn; A M Scott; S M Larson; S Welt
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

6.  Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors.

Authors:  Raymond Miralbell; Antony Lomax; Laura Cella; Uwe Schneider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-11-01       Impact factor: 7.038

7.  Second neoplasms after megavoltage radiation for pediatric tumors.

Authors:  Douglas G Gold; Joseph P Neglia; Kathryn E Dusenbery
Journal:  Cancer       Date:  2003-05-15       Impact factor: 6.860

Review 8.  Hypoxia-driven selection of the metastatic phenotype.

Authors:  Richard Sullivan; Charles H Graham
Journal:  Cancer Metastasis Rev       Date:  2007-06       Impact factor: 9.264

9.  Isolated system towards a successful radiotherapy treatment.

Authors:  Emad Moawad
Journal:  Nucl Med Mol Imaging       Date:  2010-05-01

10.  Cellular kinetics in rectal cancer.

Authors:  N H Terry; M L Meistrich; L D Roubein; P M Lynch; R A Dubrow; T A Rich
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

View more
  8 in total

1.  Clinical and pathological staging of the cancer at the nanoscale.

Authors:  Emad Y Moawad
Journal:  Cancer Nanotechnol       Date:  2012-07-22

2.  Administering the Optimum Dose of l-Arginine in Regional Tumor Therapy.

Authors:  Emad Y Moawad
Journal:  Indian J Clin Biochem       Date:  2013-09-15

3.  Induction of multiple sclerosis and response to tyrosine kinase inhibitors.

Authors:  Emad Y Moawad
Journal:  Indian J Clin Biochem       Date:  2013-09-28

4.  Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).

Authors:  Emad Y Moawad
Journal:  J Gastrointest Cancer       Date:  2015-09

5.  Optimizing bioethanol production by regulating yeast growth energy.

Authors:  Emad Y Moawad
Journal:  Syst Synth Biol       Date:  2012-11-10

6.  Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.

Authors:  Emad Y Moawad
Journal:  J Gastrointest Cancer       Date:  2015-12

7.  Identifying the optimal dose of ritonavir in the treatment of malignancies.

Authors:  Emad Y Moawad
Journal:  Metab Brain Dis       Date:  2013-11-19       Impact factor: 3.584

8.  Data to establish the optimal standard regimen and predicting the response to docetaxel therapy.

Authors:  Emad Y Moawad
Journal:  Data Brief       Date:  2015-10-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.